Status:
ACTIVE_NOT_RECRUITING
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Lead Sponsor:
Turku University Hospital
Conditions:
Gestational Diabetes
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide tre...
Detailed Description
Incidence of type 2 diabetes (T2D) is increasing along with pandemia of obesity. Gestational diabetes is the major risk factor for T2D in women and more than every tenth will develop gestational diabe...
Eligibility Criteria
Inclusion
- history of gestational diabetes with treatment with metformin and/or insulin
- delivery 6 to 18 months before screening
- BMI ≥30 kg/m2
- use of contraceptives (IU-device or oral contraceptive)
Exclusion
- lactation
- pregnancy
- type 1 or type 2 diabetes
- use of antidepressives, statins or anti-hyperglycemic therapies
- severe hepatic insufficiency
- end stage renal disease
- history of pancreatitis
Key Trial Info
Start Date :
February 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04324229
Start Date
February 7 2020
End Date
December 1 2027
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, 20521